Nadal, Ernest http://orcid.org/0000-0002-9674-5554
Horinouchi, Hidehito
Shih, Jin-Yuan
Nakagawa, Kazuhiko
Reck, Martin
Garon, Edward B.
Wei, Yu-Feng
Kollmeier, Jens
Frimodt-Moller, Bente
Barrett, Emily
Lipkovich, Olga
Visseren-Grul, Carla
Novello, Silvia
Clinical trials referenced in this document:
Documents that mention this clinical trial
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
https://doi.org/10.1007/s40264-021-01127-2
Funding for this research was provided by:
eli lilly and company
Article History
Accepted: 17 October 2021
First Online: 20 December 2021
Declarations
:
: This study was funded by Eli Lilly and Company.
: EN has received research grants from Bristol Myers Squibb, Merck Serono, Roche, and Pfizer; advisory board fees from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Amgen, Pfizer, Eli Lilly and Company, Takeda, Sanofi, Bayer, AstraZeneca, and Merck Serono; and lecturing/presentation/writing payments from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Amgen, Pfizer, Eli Lilly and Company, Takeda, Bayer, AstraZeneca, and Boehringer Ingelheim. HH has received lecture fees, honoraria, or other fees from Eli Lilly and Company, AstraZeneca, Merck Sharp & Dohme, Ono, and Bristol Myers Squibb and research grants from Merck Sharp & Dohme, Chugai, Ono, Bristol Myers Squibb, AstraZeneca, Daiichi Sankyo, Novartis, and Genomic Health. JYS has served as an advisory board member for AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Novartis, Merck Sharp & Dohme, Chugai Pharma, Ono Pharmaceutical, Takeda, CStone Pharmaceuticals, Janssen, and Bristol Myers Squibb; has received speaking honoraria from AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Novartis, Merck Sharp & Dohme, Chugai Pharma, Ono Pharmaceutical, and Bristol Myers Squibb; and has received a research grant from Roche. KN has received grants and personal fees from AstraZeneca K.K., Astellas Pharma, Merck Sharp & Dohme K.K., Ono Pharmaceutical, Nippon Boehringer Ingelheim, Novartis Pharma K.K., Pfizer Japan, Bristol Myers Squibb, Eli Lilly Japan K.K., Chugai Pharmaceutical, Daiichi Sankyo, and Merck Serono; personal fees from Medicus Shuppan, Publishers Co., Ltd, Care Net, Reno, Kyorin, Roche Diagnostics K.K., Bayer Yakuhin, Medical Mobile Communications Co., 3H Clinical Trial, Nanzando, Yodosha, Nikkei Business Publications, Thermo Fisher Scientific K.K., Yomiuri Telecasting Corporation, Nippon Kayaku, and Nichi-Iko Pharmaceutical; grants and personal fees from Takeda Pharmaceutical, Taiho Pharmaceutical, SymBio Pharmaceuticals, and AbbVie; and grants from inVentiv Health Japan, Icon Japan K.K., Gritstone Oncology, Parexel International, Kissei Pharmaceutical, EPS Corporation, Syneos Health, Pfizer R&D Japan G.K., A2 Healthcare, Quintiles Inc/IQVIA Services Japan K.K., EP-CRSU, Linical, Eisai, CMIC Shift Zero K.K., Kyowa Hakko Kirin, Bayer Yakuhin, EPS International, and Otsuka Pharmaceutical. MR has received personal fees from Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Samsung. EBG has received grants from AstraZeneca, Dynavax, Eli Lilly and Company, Genentech, Iovance, Mirati and Neon; grants and personal fees from Bristol Myers Squibb, EMD Serono, Merck, and Novartis; and personal fees from ABL, Boehringer Ingelheim, Dracen, Eisai, GSK, Sanofi, Shionogi, and Xilio. Y-FW has no conflicts of interest that are directly relevant to the content of this article. JK has served as an advisory board member for, without receiving any personal fees from, Roche Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp & Dohme, Takeda, Astra Zeneca, Amgen, and Eli Lilly and Company. BFM, EB, OL, and CVG are employees of and own stock in Eli Lilly and Company. SN has received speaker bureau/advisor personal fees from Amgen, AstraZeneca, Boehringer, Beigene, Merck Sharp & Dohme, Roche, Sanofi, Novartis, Takeda, and Pfizer.
: These clinical trial data can be requested by qualified researchers and will be provided following review and approval of a research proposal and execution of a data sharing agreement. For more information on the data request process or to submit a request, visit the following link: ExternalRef removed.
: Not applicable.
: The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments, the International Conference on Harmonisation Guidelines for Good Clinical Practice, and applicable local regulations. It was approved by the ethics committees of participating centers.
: All patients provided written informed consent prior to participation in the study.
: All authors approved this manuscript for publication.
: All authors contributed to the intellectual content of the work through conception; design; data acquisition, analysis, and interpretation; and the drafting and critical review of the manuscript. All authors provided their final approval of the manuscript.